Cardiac Troponin I
Cardiac Troponin I - Related Videos
04:40
Creation of Cardiac Tissue Exhibiting Mechanical Integration of Spheroids Using 3D Bioprinting
0 Views •
Cited by 55 •
2017
This protocol describes 3D bioprinting of cardiac tissue without the use of biomaterials. 3D bioprinted cardiac patches exhibit mechanical integration of component spheroids and are highly promising in cardiac tissue regeneration and as 3D models of heart disease.
10:12
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
0 Views •
Cited by 16 •
2013
Measuring biomarkers in complex biological samples is increasingly guiding clinical decision-making. We describe a highly sensitive method to simultaneously measure cardiac myosin binding protein-C, creatine kinase MB, and cardiac troponin I in serum samples from subjects with myocardial infarction and healthy control subjects.
07:40
Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
0 Views •
Cited by 3 •
2019
Here, we present protocols of high-intensity interval and moderate-intensity continuous exercise to observe the response of circulating cardiac troponin T (cTnT) concentration to acute exercise over 10 days. The information may assist with clinical interpretations of post-exercise cTnT elevation and guide the prescription of exercise.
06:37
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
0 Views •
Cited by 13 •
2017
We present three novel and more efficient protocols for differentiating human induced pluripotent stem cells into cardiomyocytes, endothelial cells, and smooth muscle cells and a delivery method that improves the engraftment of transplanted cells by combining cell injection with patch-mediated cytokine delivery.
09:23
Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
0 Views •
Cited by 2 •
2017
This work describes a nanoimprinting lithography method to fabricate high-quality sensing arrays that work on the principle of extraordinary optical transmission. The biosensor is low-cost, robust, easy to use, and can detect cardiac troponin I in serum at clinically relevant concentrations (99th percentile cutoff ∼10-400 pg/mL, depending on the assay).
FAQs
Damage to cardiomyocytes releases cardiac troponin I into the bloodstream, linking a measured concentration to myocardial injury. However, the result does not independently establish the specific cause of that injury. Clinicians therefore interpret the value with the patient’s symptoms and other clinical findings, rather than treating an elevated measurement as definitive evidence of one diagnosis.
Serial measurements show whether cardiac troponin I concentrations are changing over time. This pattern adds temporal information that a single measurement cannot provide and can help clinicians evaluate suspected acute myocardial infarction more effectively. The results remain part of a broader assessment that includes symptoms, electrocardiography, and imaging, because concentration changes require clinical interpretation.
An elevated cardiac troponin I concentration indicates myocardial injury but is not specific to acute myocardial infarction. Heart failure, kidney disease, and inflammation can also produce elevated levels. Recognizing these alternative clinical contexts helps prevent overinterpretation and supports a more accurate assessment when laboratory findings do not correspond clearly with the rest of the patient’s evaluation.
High-sensitivity immunoassays measure cardiac troponin I concentration in blood and make the biomarker suitable for serial evaluation. Their role is analytical: they provide the measurements used to identify changing patterns over time. Clinicians then combine those laboratory results with symptoms, electrocardiography, and imaging to determine their medical significance and guide assessment.
Evaluation combines cardiac troponin I testing with the patient’s symptoms, electrocardiography, and imaging. Clinicians examine the measured concentration and, when appropriate, its pattern across serial samples rather than relying on laboratory data alone. This integrated approach helps assess suspected acute myocardial infarction while accounting for other conditions that may cause myocardial injury.
Cardiac troponin I supports several clinical decisions, including faster diagnostic assessment, cardiovascular risk stratification, and treatment planning. Its value extends beyond identifying a possible acute myocardial infarction because the measured level and its time-related pattern can contribute to judging cardiovascular risk. Interpretation still depends on the broader clinical context and associated findings.